Nureca Limited has announced the dissolution of its wholly owned subsidiary, Nureca Healthcare Private Limited, effective December 3, 2025. This corporate action, carried out under Section 248 of the Companies Act, 2013, marks a significant development in the company's structure.

Key Points of the Announcement

• Subsidiary Dissolved: Nureca Healthcare Private Limited
• Effective Date: December 3, 2025
• Legal Basis: Section 248 of the Companies Act, 2013
• Regulatory Compliance: Informed BSE and NSE as per SEBI regulations

Implications and Context

The striking off of a wholly owned subsidiary often indicates a strategic move by the parent company. While the specific reasons for this action have not been disclosed, such decisions are typically made to streamline operations, reduce administrative overhead, or realign business focus.

Regulatory Compliance

Nureca Limited has adhered to regulatory requirements by promptly informing the stock exchanges. This transparency is crucial for maintaining investor trust and complying with the Securities and Exchange Board of India (SEBI) regulations.

What This Means for Investors

Investors should note that this corporate action might have implications for Nureca Limited's financial structure and operations. However, without further details, it's premature to speculate on the exact impact on the company's future performance or stock value.

Shareholders and potential investors are advised to:

• Monitor any subsequent announcements from the company for additional context
• Review future financial reports to understand any material changes resulting from this dissolution
• Consult with financial advisors if seeking personalized investment advice related to this development

As the market digests this information, it will be important to observe any changes in Nureca Limited's stock performance and analyst recommendations in the coming days.

Nureca Limited has announced plans to hold a board meeting on November 28 to discuss a potential share buyback program. This corporate action indicates the company's consideration of returning capital to shareholders through share repurchases.

Key Details of the Announcement

Regulatory Compliance

The company has adhered to regulatory requirements by informing the stock exchanges about this agenda item. This disclosure aligns with Regulation 29(1)(b) of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

Implications for Shareholders

If a buyback is approved, it could have several implications for Nureca's shareholders:

• Potential increase in earnings per share
• Possible positive impact on the stock price
• Opportunity for shareholders to tender their shares

It's important to note that the board meeting will only consider the buyback proposal. The final decision, including details such as the buyback size, price, and method, will be subject to board approval and subsequent regulatory processes.

Company Information

Nureca Limited, with its registered office in Mumbai and correspondence office in Chandigarh, operates under the Corporate Identification Number (CIN) L24304MH2016PLC320868. The company has made this information available on its official website, www.nureca.com , ensuring transparency in its communications with stakeholders.

Investors and market participants are advised to await the outcome of the board meeting for further details on the potential buyback. As always, it's recommended to consult with financial advisors before making any investment decisions based on this development.